Skip to content
Company Analysis

Amneal Pharmaceuticals, Inc. AMRX

A comprehensive view of key metrics, scores, and financial health for Amneal Pharmaceuticals, Inc.

Overview of Amneal Pharmaceuticals, Inc.

AMRX NMS
Healthcare Drug Manufacturers - Specialty & Generic Mid Cap
Amneal Pharmaceuticals, Inc. (AMRX), is a Mid Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $11.83, about 52.0% undervalued vs fair value, +37.2% 1Y return, ranked 298/1110 in sector.
$11.83
-2.35%
As of March 13, 2026
Previous close • Vol 90d: 34.8%
52-Week Range
Market Cap
$3.72B
Enterprise Value
$6.21B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Amneal Pharmaceuticals, Inc..

Top Beats

Quick Facts

Website https://www.amneal.com
HQ Bridgewater, NJ
Employees 8,300
Fiscal year Dec 31

Next Events

Earnings May 1 Estimated

Fair Value Snapshot

Bear Base Bull
$16
$18
$20
Current: $11.83 +52% vs base

Engine Room Money Flow™

Mid Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$2.8B
16.7%%
Gross Profit
$1.0B
24.4%%
R&D Expense
$196.6M
17.2%%
Operating Income (EBIT)
$203.6M
19.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
145.0%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$11.5M
5.2% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
1
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Amneal Pharmaceuticals, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
64
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
68
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing AMRX's balance between Growth (34.9%), Profitability (38.4%), and Safety (26.8%). Growth 35% Safety 27% Profitability 38%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

63th percentile vs peers
63
Key Signals
Rev Growth YoY 16.7% 67p Revenue CAGR 3Y 10.1% 61p EPS Growth YoY 20.7% 46p TSR 1.88 86p
Strengths
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (85%)
  • Tsr in top 20% of peers (1.88, 86th percentile)
  • Roic in top 20% of peers (11.6%, 83th percentile)
Risks

No significant risks identified for this axis.

Profitability

69th percentile vs peers
69
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

48th percentile vs peers
48
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Amneal Pharmaceuticals, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$17.98
- - -
+52.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info